Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters

Database
Language
Publication year range
1.
J Eur Acad Dermatol Venereol ; 25(8): 896-901, 2011 Aug.
Article in English | MEDLINE | ID: mdl-21054566

ABSTRACT

BACKGROUND: Photodynamic therapy (PDT) is increasingly used in the treatment of basal cell carcinoma (BCC). However, scant information is available about the impact of both patient- and lesion-related characteristics on the effectiveness of therapy. Therefore, on the basis of the current data, it is difficult to draw clear-cut indications to use PDT for treatment of BCC in clinical practice. OBJECTIVE: To investigate the clinical and pathological determinants of response of BCC to PDT with methylaminolevulinate (MAL) and red light. METHODS: The clinical and pathological characteristics of 194 BCCs in 135 patients, treated with MAL-PDT, were evaluated. Lesions were treated with MAL-PDT according to established methods and the response was assessed by clinical follow-up of the patients. RESULTS: Complete response to PDT was 62%, with a better response for superficial BCC (95/116, 82%) than nodular BCC (26/78, 33%). When determinants of response were analysed, the nodular type and the location on the limbs emerged as significant clinical predictors of failure. Among the pathological characteristics, the nodular and infiltrative histotypes, as well as ulceration and tumour thickness were associated with a lower response to therapy. Patients' age and gender, as well as the size of the lesions, were not found to be significant predictors. CONCLUSIONS: Optimization of PDT procedure for BCC requires a careful selection of the lesions. In particular, superficial BCCs, preferentially located on the trunk, show the best therapeutic response.


Subject(s)
Aminolevulinic Acid/analogs & derivatives , Carcinoma, Basal Cell/drug therapy , Carcinoma, Basal Cell/pathology , Photochemotherapy , Photosensitizing Agents/therapeutic use , Skin Neoplasms/drug therapy , Skin Neoplasms/pathology , Age Factors , Aged , Aged, 80 and over , Aminolevulinic Acid/therapeutic use , Extremities/pathology , Female , Head and Neck Neoplasms/drug therapy , Head and Neck Neoplasms/pathology , Humans , Male , Middle Aged , Retrospective Studies , Sex Factors , Torso/pathology , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL